pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 91
- Drugs
- 36
- Patents
- 175
PARP inhibitor BMN-673
Phase 1 · small molecule · Metastatic Cancer
PARP inhibitor BMN-673 for Metastatic Cancer is a Phase 1 program (small_molecule) at BioMarin Pharmaceutical Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code 13-001857
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioMarin Pharmaceutical Australia Pty Ltd
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Metastatic Cancer
- Status
- completed
- Trials
- 1